See what you meant on oz-biz @KainCarver The analysts a blithering idiot - no idea on the stock obviously. Not unlike some investors it seems; selling here.
It seems the Western Australian knows how to read progressing sales in a 4C at least, if the market doesn't;
A near 40% revenue growth for the quarter, YoY, strong revenue growth indeed, and when you back at accrued revenues, actual cash sales receipts +111% for the quarter, YoY, and for better perspective, trailing yearly cash flows (i.e. the last 4 qtrs combined versus previous corresponding) growing at +55% YoY. You'd think some of these analysts would be able to do a bit of quick extrapolation of basic accounting figures under interview.
At the risk of teaching some people to suck eggs, as cash receipts are now the larger part of quarterly revenues (>recognised accrued BH revenue; R&D rebate; interest on [significant] cash; etc) that OCC tends to headline with on the 4C's (it wanted to get in those chunky BioHorizon accrued revenues early on its youthful accounting sheets given their significance) will, through natural laws of mathematics, cash sales receipts will start dominating reported revenue growth figures, particularly when US Remplir sales hit - ex-US Remplir sales are evidently starting too, if the lack of normally seen falling 3Q vs 2Q, QoQ sales receipts any indication.
Sales figures, IMO, will in the next two quarters leave the recent linear growth pattern and start to go exponential naturally (as then revenues) and then more significantly with US Remplir sales hitting properly 4Q 25CY (2Q 26FY). A half decent analyst might have deduced and flagged the same. Some of that already priced into the stock of course, but mkts seem less forward looking lately.
Some guidance from the company would not have gone amiss. My estimates on cash sales, for 4Q 25FY is $1.75M (+/- 0.05) and 1Q 26FY, $2.20M (+/- 0.1). If those seem excessive, they've seen larger % QoQ gains in the recent comparable periods. As for what 2Q 26FY sales receipts are when US remplir sales really kick in, other informed investors estimates are likely just as good as mine. I personally estimate/model OCC running cash flow neutral by 3Q26FY (i.e. 1Q 26CY) and of course prior quarters cash burn steadily diminishing, so the vast majority of the $31 million cash the company has on hand, still on hand commencing 2026. Some idiots trying to FUD a CR, just that, idiotic - operational cash burn (including rebate) for this financial year is unlikely to be much more than $7M before the improvements!
(not to say OCC SP won't go a bit lower before - Nividia write-downs hitting US have little implication for me, but its probably risk off tonight in the US mkt again)
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)